BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a note issued to investors on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their price objective on BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a report on Monday, November 25th.

BioLineRx Stock Performance

Shares of BLRX opened at $0.20 on Wednesday. BioLineRx has a one year low of $0.19 and a one year high of $1.70. The company has a market cap of $16.15 million, a PE ratio of -0.92 and a beta of 1.39. The stock has a 50-day moving average of $0.37 and a 200-day moving average of $0.56. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. PVG Asset Management Corp acquired a new stake in shares of BioLineRx in the 2nd quarter worth about $70,000. Atria Investments Inc raised its stake in shares of BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares during the last quarter. Finally, CVI Holdings LLC purchased a new position in shares of BioLineRx during the second quarter valued at approximately $462,000. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.